A safety estimand for late phase clinical trials where the analysis period varies over the subjects

CONCLUSION: It is valuable, and possible, to use the International Council for Harmonisation estimand framework not only for efficacy but also for safety evaluation, with the estimand driven by an interpretable, and relevant, clinical question.PMID:38425019 | DOI:10.1177/17407745241230933
Source: Clinical Trials - Category: Research Authors: Source Type: research